about
Prognostic significance of adverse events in patients with hepatocellular carcinoma treated with sorafenibAnti-angiogenic agents in metastatic colorectal cancerFirst- and Second-Line Targeted Systemic Therapy in Hepatocellular Carcinoma-An Update on Patient Selection and Response EvaluationSynergistic inhibitory effect of hyperbaric oxygen combined with sorafenib on hepatoma cellsA single-center experience of sorafenib monotherapy in patients with advanced intrahepatic cholangiocarcinoma.Baicalein induces apoptosis and autophagy via endoplasmic reticulum stress in hepatocellular carcinoma cellsTranscriptomic responses provide a new mechanistic basis for the chemopreventive effects of folic acid and tributyrin in rat liver carcinogenesis.Feasibility and safety of sorafenib treatment in hepatocellular carcinoma patients with spontaneous rupture.Evaluating the role of treatment-related toxicities in the challenges facing targeted therapies for advanced hepatocellular carcinoma.Evaluation of sorafenib in Chinese unresectable hepatocellular carcinoma patients with prior surgery and portal vein tumor thrombosis: A subset analysis of GIDEON study data.Sorafenib in metastatic uveal melanoma: efficacy, toxicity and health-related quality of life in a multicentre phase II study.Thyroid dysfunctions induced by tyrosine kinase inhibitors.Refining sorafenib therapy: lessons from clinical practice.The adverse effects of sorafenib in patients with advanced cancers.Keratoacanthoma: a distinct entity?Survival Estimates after Stopping Sorafenib in Patients with Hepatocellular Carcinoma: NEXT Score Development and Validation.HDAC6-mediated EGFR stabilization and activation restrict cell response to sorafenib in non-small cell lung cancer cells.Sorafenib in the treatment of hepatocellular carcinoma: a multi-centre real-world study.Antibody-Mediated Blockade of Phosphatidylserine Enhances the Antitumor Effect of Sorafenib in Hepatocellular Carcinomas Xenografts.Targeting multiple oncogenic pathways for the treatment of hepatocellular carcinoma.Glycine inhibits angiogenic signaling in human hepatocellular carcinoma cells.Systemic treatment for hepatocellular carcinoma: Still unmet expectationsPrognostic significance of sarcopenia in patients with hepatocellular carcinoma undergoing sorafenib therapy.Novel Pretreatment Scoring Incorporating C-reactive Protein to Predict Overall Survival in Advanced Hepatocellular Carcinoma with Sorafenib TreatmentDes-gamma-carboxy prothrombin antagonizes the effects of Sorafenib on human hepatocellular carcinoma through activation of the Raf/MEK/ERK and PI3K/Akt/mTOR signaling pathways.Safety and Efficacy of Transarterial Radioembolization Combined with Chemoembolization for Bilobar Hepatocellular Carcinoma: A Single-Center Retrospective Study.Proposal of Japan Red Cross score for sorafenib therapy in hepatocellular carcinoma.Effects of Antitumor Drug Sorafenib on Chick Embryo Development.Inhibition of pMAPK14 Overcomes Resistance to Sorafenib in Hepatoma Cells with Hepatitis B Virus.Biomacromolecule/lipid hybrid nanoparticles for controlled delivery of sorafenib in targeting hepatocellular carcinoma therapy.Hepatocellular Carcinoma Treatment With Sorafenib: Real-Life Evaluation of Prognostic Factors and a Practical Clue for Patient Management.Liver Protective Effects of Renin-Angiotensin System Inhibition Have No Survival Benefits in Hepatocellular Carcinoma Induced By Repetitive Administration of Diethylnitrosamine in Mice.
P2860
Q26765210-CCA607F5-F859-4D16-BE82-A6A24DD936B4Q26801911-27387D3E-AFA6-491B-BCCB-9F06897C5DE8Q28073654-9A6DA8E9-7550-42EB-BD39-2C4516312DCFQ28539940-552F255F-2D17-470F-8139-91F80615208DQ33686690-1CB91ED2-5D3E-4F3C-8024-BD78A21DAE36Q33786747-24980DDF-AE2D-433B-868F-54F686C60EA4Q34496914-09C78940-979C-4C1E-B627-1A4D5A8D66C8Q34552160-C784BB56-BB73-416E-B5C4-85970E6354C9Q35739362-A9853568-2FDC-47C6-9992-E6C9A3DFE2E9Q36325065-A3CC019F-6522-4907-9B1D-73E3B50BCAC6Q37061324-10F31EC6-0125-4D06-8BFD-DC7EB700D2E3Q38211342-AB20C5F6-9E0B-4E23-8D5F-5FFD4631F394Q38264146-A19CDDCA-9E18-4EC4-B795-7DEFC678389CQ38286308-8170DEB4-E5E0-4875-86D8-E17CB8A1751AQ38609786-36A1E476-9B9E-4465-AC5D-94F070E126D5Q38708569-C7F1B514-58D6-4043-BE4C-4197750DA334Q38777310-FFFDDA6A-DE4F-42B7-83A2-9ABF33B69F46Q38830457-6C374CF9-F9CB-427B-9AB4-33689E94FD46Q38911797-8DC50C18-54E1-4DF4-B691-AEA999E5E41CQ38923977-4AB6AA5F-6412-4CAC-B88E-8E05CD6C947CQ39037350-069CC4BC-AD85-4F7F-B603-5C83E7C45049Q39112745-036884D9-DE13-4434-A033-1563875042F1Q41143489-91E23F82-9694-4EE1-9F14-36E0CB69E709Q41544562-379F115B-F05A-4388-989C-2669EFDF51E9Q41667581-9F5D44E2-B4A9-4A94-9AE9-DDCB01AC96B9Q47724444-CCC24F9B-3EC6-41B9-9D63-4D82E5D9C7AAQ50453658-C27505A6-E1D3-445E-AD49-F5C69ECAB7F0Q50594719-6455F072-94F7-49E2-B480-B1129F8F4993Q52663015-D8754CC4-7A28-4AA3-B8B6-DD84423859B3Q53639202-492C7A7C-2539-4CB0-9DF3-1C2DC07C9F01Q53820145-68256C66-4249-4DA4-8CB5-634B97475216Q55426501-804566D6-BEA1-4660-96EF-87F00913BA58
P2860
description
2013 nî lūn-bûn
@nan
2013 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Sorafenib: from literature to clinical practice
@ast
Sorafenib: from literature to clinical practice
@en
Sorafenib: from literature to clinical practice
@nl
type
label
Sorafenib: from literature to clinical practice
@ast
Sorafenib: from literature to clinical practice
@en
Sorafenib: from literature to clinical practice
@nl
prefLabel
Sorafenib: from literature to clinical practice
@ast
Sorafenib: from literature to clinical practice
@en
Sorafenib: from literature to clinical practice
@nl
P2093
P2860
P3181
P356
P1433
P1476
Sorafenib: from literature to clinical practice
@en
P2093
C. Verslype
F. De Vita
J. Koskinas
P. Toniutto
V. Di Marco
P2860
P304
P3181
P356
10.1093/ANNONC/MDT055
P407
P478
24 Suppl 2
P577
2013-04-01T00:00:00Z